AIM: The aim of this study was to investigate the polymorphism frequency of plasminogen activator inhibitor-1 (PAI-1) (rs1799889) 4G/5G in patients with lung cancer. METHODS: In this study, 286 genomic DNAs (154 lung cancer patients+132 subjects without lung cancer) were analyzed. Polymorphisms were determined by using the polymerase chain reaction (PCR) method, with 4G and 5G allele-specific primers. PCR products were assessed by a charge-coupled device camera and exposed to 2% agarose gel electrophoresis. RESULTS: The frequencies of the PAI-1 gene 4G/5G genotypes were found to be 21% 4G/4G, 16% 4G/5G, and 62% 5G/5G in the control group and 31.4% 4G/4G, 30.8% 4G/5G, and 37.8% 5G/5G in the patient group. It was determined that the 5G/5G genotype frequency was high in patients in comparison with other genotypes. CONCLUSIONS: This study found a statistically significant difference between the groups with respect to genotype distribution. Consequently, we can say that the PAI-1 gene 4G/5G polymorphism is associated with lung cancer in Turkey.
AIM: The aim of this study was to investigate the polymorphism frequency of plasminogen activator inhibitor-1 (PAI-1) (rs1799889) 4G/5G in patients with lung cancer. METHODS: In this study, 286 genomic DNAs (154 lung cancerpatients+132 subjects without lung cancer) were analyzed. Polymorphisms were determined by using the polymerase chain reaction (PCR) method, with 4G and 5G allele-specific primers. PCR products were assessed by a charge-coupled device camera and exposed to 2% agarose gel electrophoresis. RESULTS: The frequencies of the PAI-1 gene 4G/5G genotypes were found to be 21% 4G/4G, 16% 4G/5G, and 62% 5G/5G in the control group and 31.4% 4G/4G, 30.8% 4G/5G, and 37.8% 5G/5G in the patient group. It was determined that the 5G/5G genotype frequency was high in patients in comparison with other genotypes. CONCLUSIONS: This study found a statistically significant difference between the groups with respect to genotype distribution. Consequently, we can say that the PAI-1 gene 4G/5G polymorphism is associated with lung cancer in Turkey.
Authors: Sachin Yende; Derek C Angus; Jingzhong Ding; Anne B Newman; John A Kellum; Rongling Li; Robert E Ferrell; Joseph Zmuda; Stephen B Kritchevsky; Tamara B Harris; Melissa Garcia; Kristine Yaffe; Richard G Wunderink Journal: Am J Respir Crit Care Med Date: 2007-08-29 Impact factor: 21.405
Authors: Deborah French; Leo H Hamilton; Leonard A Mattano; Harland N Sather; Meenakshi Devidas; James B Nachman; Mary V Relling Journal: Blood Date: 2008-02-19 Impact factor: 22.113
Authors: H Trimarchi; C Duboscq; V Genoud; F Lombi; A Muryan; P Young; M Schwab; M Castanon; E Rodriguez-Reimundes; M Forrester; H Pereyra; V Campolo-Girard; O Seminario; M Alonso; L Kordich Journal: J Vasc Access Date: 2008 Apr-Jun Impact factor: 2.283